ARCHIVES

Revlimid Maintenance Therapy Delayed Progression by 90%

This article is from The Cancer Letter archive.

Vol. 34 No. 5 | May 27, 2011

Download PDF Visit The Full Archive

Related Articles

Funding opportunities listed.

March 26, 2004

Gene Vector Labs Seek Vector Producers

February 23, 1996

In Brief: Bioassay Prime Contract Renewed For Four Years, $34.2 Million; Canellos Quits As Clinical Director

June 20, 1975

Executive Committee, Board of Scientific Advisors concur.

January 2, 2004

ASCO Draft Recommendations Define Meaningful Trial Outcomes

April 26, 2013

As von Eschenbach Prepares For New Assignment, NCI’s 2015 Goal Faces Uncertainty. New Strategic Plan Lists Steps to 2015. “The Vision Is Within Our Grasp,” von Eschenbach Says.

March 10, 2006